Clinical research
AbbVie and Genmab announced positive topline results from their Phase I/II trial for lymphoma treatment; Sanofi posted positive results from its Phase I/II trial for the treatment of ITP.
The revised operating plan also includes reductions in spending related to general and administrative expenses and investments in its research platform.
Drug pricing watchdog ICER issued a draft report on bluebird bio’s gene therapy betibeglogene autotemcel for beta-thalassemia. The report touted the therapy’s cost-effectiveness.
Pfizer and BioNTech will submit updated data to the FDA to support the Emergency Use Authorization (EUA) of COVID-19 vaccination boosters in children between the age of 5 and 11.
Protagonist disclosed the FDA issued a letter of intent to rescind the status for rusfertide based on concerns first raised in a clinical hold placed on the drug.
The AACR annual meeting concluded on April 13, showcasing hundreds of preclinical to late-stage information from ongoing studies on treatment candidates.
ProQR Therapeutics, which is developing RNA therapies for genetic eye diseases, announced Wednesday that it will be restructuring and laying off 30% of its staff.
This year’s AACR Annual Meeting is coming to a close, and there has been a wealth of information and data presented. One topic of discussion stood out—mutations.
As the American Association of Cancer Research (AACR) Annual Meeting wraps up, there were some surprising and exciting research news and presentations.
As the world speculates the potential impact of the novel COVID-19 variant omicron XE and subvariant BA.2, research continues to shed light on the impact and future of the pandemic.
PRESS RELEASES